Plenary Session
Session 1 – Multidisciplinary implementation strategies
Chairs – Andrew Coats & Manisha Sahay
- Multi-level implementation strategies to improve uptake of evidence-based therapies in heart failure – Gianluigi Savarese
- Screening of HF in diabetes: when and why? – Francesco Cosentino
- CRM disease in the primary care setting – Sam Seidu
- Panel Discussion
Meet the Experts
Keynote Session
- KDIGO guideline updates 2024 – Paul Stevens
Plenary Session
Session 2 – Guideline directed therapy for CRM disease: the evidence base
Chairs – Intissar Haddiya & Lars Lund
-
Guideline directed medical therapy in HF across the LVEF spectrum – Marco Metra
-
ESC guidelines for the management of CV disease in patients with diabetes – Nikolaus Marx
-
Management of diabetes with kidney disease – Peter Rossing
-
Panel Discussion
Meet the Experts
SGLT2i: best practices in implementation across HF, diabetes and CKD
Chair – Michel Jadoul
-
SGLT2 inhibition across T2DM, CKD and HF: evidence base and rationale for early initiation – Clara Inés Saldarriaga
-
Practical guidance for the use of SGLT2 inhibitors in patients with cardio-renal-metabolic disease – Shelley Zieroth
-
Panel Discussion
Supported by an unrestricted educational grant from AstraZeneca
Meet the Experts
Management of hyperkalemia best practices
-
The challenge of GDMT implementation in patients with heart failure and comorbidities: patient profiling and potassium management – Gianluigi Savarese
-
Optimising RAAS inhibitor therapy in patients with chronic kidney disease and comorbidities: long-term hyperkalemia management in practice – James Burton
-
Panel Discussion
Supported by an unrestricted educational grant from AstraZeneca
Plenary Session
Session 3 – Managing the patients with CRM: who gets what, when and why?
Chairs – Gianluigi Savarese & Alice Cheng
-
The nephrologist view – Adeera Levin
-
The diabetologist view – Antonio Ceriello
-
The cardiologist view – Shelley Zieroth
-
Panel Discussion
Meet the Experts
Optimisation of guideline-directed medical therapy in cardiorenal patients: overcoming the barrier of hyperkalemia
Chair – Ileana Piña
-
Guideline-directed medical therapy in cardiorenal patients: advances and implementation gaps – Iris Beldhuis
-
Long-term hyperkalemia management in cardiorenal patients: potassium binders as enabling therapy – David Wheeler
-
Panel Discussion
Supported by an unrestricted educational grant from CSL Vifor
Plenary Session
Session 4 – Weight homeostasis management in CRM disease
Chairs – Scott Isaacs & Peter Rossing
Impact of weight loss in CRM disease – Muthiah Vaduganathan
How can cardiologists manage excess body weight? – Stefan Anker
GLP1-Ra: a role as next HF drug? – Javed Butler
Panel Discussion
Organised with support from Charité Friends & Sponsors Trust
Plenary Session
Session 5 – CRM disease: epidemiology and pathophysiology
Chairs – Ahmed Bennis & Ileana Piña
-
Prevalence and overlap of cardiac, renal and metabolic conditions – Giulia Ferrannini
-
Cardiovascular-kidney-metabolic syndrome: a consensus definition – Chiadi Ndumele
-
Heart failure: an underappreciated complication of diabetes – Rodica Pop-Busui
-
Panel Discussion
Meet the Experts
Replay of Keynote Session
-
KDIGO guideline updates 2024 – Paul Stevens
Plenary Session
Session 6 – Anaemia and iron deficiency
Chairs – John Cleland & Gerasimos Filippatos
-
Update on IV iron – Ewa Jankowska
-
Novel anaemia therapies in chronic kidney disease: conclusions from a KDIGO Controversies Conference – David Wheeler
-
IV iron use in the era of SGLT2 inhibitors: what should physicians know – Kieran Docherty
-
Panel Discussion
Meet the Experts
Practical implementation of non-steroidal mineralocorticoid receptor antagonists to reduce cardiorenal risk
Muthiah Vaduganathan & David Charytan
Plenary Session
Session 7 – Clinical presentations and treatment across the patient journey: focus on CKD and CVD
Chairs – Michel Jadoul & Stephan Von Haehling
-
Biological differences between men and women – Sofia Ahmed
-
Life span considerations (from birth to young adults) – Rukshana Shroff
-
Life span considerations (ageing and the older person) – Elke Schaeffner
-
Panel Discussion
Plenary Session
Session 8 – Early intervention and intensive management
Chairs – Nooshin Bazargani & Vijay Chopra
-
Comprehensive management of the patient with CRM disease – Deepak Bhatt
-
Myth busting potassium management in CRM disease – Michelle Wong
-
The role of new non-steroidal MRAs – George Bakris
-
Panel Discussion
Meet the Experts
Effects of GLP- 1RA on kidney outcomes in CKD and T2D
Stefan Anker & Peter Rossing
Plenary Session
Session 9 – Precision medicine in CRM
Chairs – Paul Stevens & Harriette Van Spall
-
Novel risk prediction equations (cardiac disease) – Josef Coresh
-
Novel risk prediction equations (kidney disease) – Navdeep Tangri
-
Translational science (target pathways) – Wenjun Ju
-
Panel Discussion
Dr Sofia Ahmed
University of Calgary, Calgary, CA
Prof Stefan Anker
Charité Campus Virchow-Klinikum, Berlin, DE
Prof George Bakris
University of Chicago, Illinois, US
Dr Nooshin Bazargani
Dubai Health Authority, Dubai, AE
Dr Iris Beldhuis
University Medical Center Groningen, Groningen, NL
Prof Ahmed Bennis
Ibn Rochd University Hospital, Casablanca, MA
Prof Deepak Bhatt
Mount Sinai Heart, New York, US
Prof James Burton
University of Leicester, Leicester, UK
Dr Javed Butler
Baylor Scott and White Research Institute, Texas, US
Prof Antonio Ceriello
IRCCS MultiMedica, Milan, IT
Dr David Charytan
NYU Langone Health, New York, US
Dr Alice Cheng
University of Toronto, Toronto, CA
Prof John Cleland
University of Glasgow, Glasgow, UK
Prof Andrew Coats
Heart Research Institute, NSW, AU
Dr Josef Coresh
Johns Hopkins Bloomberg School of Public Health, Maryland, US
Prof Francesco Cosentino
Karolinska Institute, Stockholm, SE
Dr Kieran Docherty
University of Glasgow, Glasgow, UK
Dr Giulia Ferrannini
Karolinska Institute, Stockholm, SE
Prof Gerasimos Filippatos
National and Kapodistrian University of Athens, Athens, GR
Prof Intissar Haddiya
Mohamed First University, Oujda, MA
Prof Scott Isaacs
Atlanta Endocrine Associates, Georgia, US
Prof Michel Jadoul
Université catholique de Louvain, Louvain-la-Neuve, BE
Prof Ewa Jankowska
Wrocław Medical University, Wrocław, PL
Dr Wenjun Ju
University of Michigan Medical School, Michigan, US
Dr Adeera Levin
University of British Columbia, Vancouver, CA
Prof Lars Lund
Karolinska University Hospital, Stockholm, SE
Prof Nikolaus Marx
RWTH University Hospital Aachen, Aachen, DE
Prof Marco Metra
University of Brescia, Brescia, IT
Dr Chiadi Ndumele
The Johns Hopkins Hospital, Maryland, US
Dr Ileana Pina
Thomas Jefferson University, Philadelphia, US
Prof Rodica Pop-Busui
University of Michigan Medical Center, Michigan, US
Giuseppe Rosano
St Georges Medical School, London, UK
Prof Peter Rossing
University of Copenhagen, Copenhagen, DK
Dr Manisha Sahay
Osmania General Hospital, Hyderabad, IN
Prof Clara Inés Saldarriaga
University of Antioquia, Medellín, CO
Dr Gianluigi Savarese
Karolinska Institute, Stockholm, SE
Dr Elke Schaeffner
Charité – Universitätsmedizin Berlin, Berlin, DE
Prof Sam Seidu
University of Leicester, Leicester, UK
Dr Rukshana Shroff
Great Ormond Street Hospital, London, UK
Dr Paul Stevens
East Kent Hospitals University NHS Foundation Trust, Canterbury, UK
Dr Navdeep Tangri
University of Manitoba, Winnipeg, CA
Prof Muthiah Vaduganathan
Brigham and Women's Hospital, Massachusetts, US
Prof Harriette Van Spall
McMaster University, Hamilton, CA
Prof Stephan Von Haehling
University Medical Center Göttingen, Göttingen, DE
Prof David Wheeler
University College London, London, UK
Dr Michelle Wong
The University of British Columbia, Vancouver, CA
Prof Shelley Zieroth
St. Boniface Hospital, Winnipeg, CA
